
Lukas Carter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9502488/publications.pdf Version: 2024-02-01



LINKAS CADTED

#	Article	IF	CITATIONS
1	Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity. Clinical Cancer Research, 2022, 28, 1391-1401.	7.0	19
2	PET Imaging of Acidic Tumor Environment With 89Zr-labeled pHLIP Probes. Frontiers in Oncology, 2022, 12, .	2.8	11
3	Delta-like ligand 3–targeted radioimmunotherapy for neuroendocrine prostate cancer. Proceedings of the United States of America, 2022, 119, .	7.1	17
4	Imaging Early-Stage Metastases Using an 18F-Labeled VEGFR-1-Specific Single Chain VEGF Mutant. Molecular Imaging and Biology, 2021, 23, 340-349.	2.6	6
5	Technical Note: Patientâ€morphed meshâ€type phantoms to support personalized nuclear medicine dosimetry — a proof of concept study. Medical Physics, 2021, 48, 2018-2026.	3.0	2
6	REPLY TO LETTER TO THE EDITOR: POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19. Journal of Nuclear Medicine, 2021, 62, jnumed.121.261950.	5.0	0
7	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate Chemistry, 2021, 32, 649-654.	3.6	6
8	Patient Size-Dependent Dosimetry Methodology Applied to ¹⁸ F-FDG Using New ICRP Mesh Phantoms. Journal of Nuclear Medicine, 2021, 62, 1805-1814.	5.0	7
9	Personalized dosimetry of ¹⁷⁷ Lu-DOTATATE: a comparison of organ- and voxel-level approaches using open-access images. Biomedical Physics and Engineering Express, 2021, 7, 057002.	1.2	4
10	Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe. Clinical Cancer Research, 2021, 27, 6145-6155.	7.0	8
11	The Impact of Positron Range on PET Resolution, Evaluated with Phantoms and PHITS Monte Carlo Simulations for Conventional and Non-conventional Radionuclides. Molecular Imaging and Biology, 2020, 22, 73-84.	2.6	50
12	An ⁸⁹ Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. Journal of Nuclear Medicine, 2020, 61, 433-436.	5.0	25
13	Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect. Theranostics, 2020, 10, 567-584.	10.0	63
14	CAR Chase: Where Do Engineered Cells Go in Humans?. Frontiers in Oncology, 2020, 10, 577773.	2.8	7
15	Oncology-Inspired Treatment Options for COVID-19. Journal of Nuclear Medicine, 2020, 61, 1720-1723.	5.0	15
16	pHLIP ICG for delineation of tumors and blood flow during fluorescence-guided surgery. Scientific Reports, 2020, 10, 18356.	3.3	19
17	First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. Journal of Nuclear Medicine, 2020, 61, 1580-1587.	5.0	5
18	CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Radiology, 2020, 295, 606-615.	7.3	73

LUKAS CARTER

#	Article	IF	CITATIONS
19	iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. Cancer Research, 2020, 80, 1681-1692.	0.9	31
20	Targeted Brain Tumor Radiotherapy Using an Auger Emitter. Clinical Cancer Research, 2020, 26, 2871-2881.	7.0	69
21	Fluorescence labeling of a NaV1.7-targeted peptide for near-infrared nerve visualization. EJNMMI Research, 2020, 10, 49.	2.5	10
22	3D-Printable Platform for High-Throughput Small-Animal Imaging. Journal of Nuclear Medicine, 2020, 61, 1691-1692.	5.0	3
23	Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. Journal of Nuclear Medicine, 2019, 60, 1569-1578.	5.0	27
24	PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms. Journal of Nuclear Medicine, 2019, 60, 1802-1811.	5.0	27
25	Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2019, 25, 868-880.	7.0	55
26	Metal-based Radiotherapeutics. 2-Oxoglutarate-Dependent Oxygenases, 2019, , 271-307.	0.8	0
27	Preclinical optimization of antibodyâ€based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 611-635.	1.0	24
28	PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine, 2018, 59, 1225-1233.	5.0	51
29	ICP-MS measurement of silver diffusion coefficient in graphite IG-110 between 1048K and 1284K. Journal of Nuclear Materials, 2018, 498, 44-49.	2.7	7
30	Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nature Communications, 2018, 9, 5137.	12.8	78
31	Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Journal of Nuclear Medicine, 2018, 59, 1894-1900.	5.0	36
32	Sorption of Ag and its vaporization from graphite at high temperatures. Journal of Nuclear Materials, 2017, 493, 132-146.	2.7	5
33	Multiplexed imaging for diagnosis and therapy. Nature Biomedical Engineering, 2017, 1, 697-713.	22.5	133
34	Diffusion of cesium and iodine in compressed IG-110 graphite compacts. Journal of Nuclear Materials, 2016, 476, 30-35.	2.7	10
35	Calibration of a system for measurements of diffusion coefficients of fission products in HTGR/VHTR core materials. Journal of Radioanalytical and Nuclear Chemistry, 2016, 307, 1771-1775.	1.5	6
36	ICP-MS measurement of iodine diffusion in IG-110 graphite for HTGR/VHTR. Journal of Nuclear Materials, 2016, 473, 218-222.	2.7	9

#	Article	IF	CITATIONS
37	ICP-MS measurement of diffusion coefficients of Cs in NBG-18 graphite. Journal of Nuclear Materials, 2015, 466, 402-408.	2.7	11
38	Measurement of cesium diffusion coefficients in graphite IG-110. Journal of Nuclear Materials, 2015, 460, 30-36.	2.7	16